stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) Return on invested capital
Dr. Reddy's Laboratories Ltd's return on invested capital over the twelve months to 30 September 2026 was 4.77%, down 3.8 percentage points from fiscal 2026 (8.55%). Over the past ten years it has ranged from 4.78% (fiscal 2018) to 19.7% (fiscal 2023); the current reading is higher than 33% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | 8.55% | (5.27) |
| FY2025 | 13.8% | (5.49) |
| FY2024 | 19.3% | (0.37) |
| FY2023 | 19.7% | 9.32 |
| FY2022 | 10.4% | (1.89) |
| FY2021 | 12.3% | (1.39) |
| FY2020 | 13.6% | 5.13 |
| FY2019 | 8.51% | 3.73 |
| FY2018 | 4.78% | (0.67) |
| FY2017 | 5.45% | (9.76) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 57.7% |
| NBIX Neurocrine Biosciences, Inc. compare | 17.7% |
| LNTH Lantheus Holdings, Inc. compare | 14.6% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 8.45% |
| RDY Dr. Reddy's Laboratories Ltd | 4.77% |
| ALKS Alkermes plc compare | 1.54% |
| ELAN Elanco Animal Health Incorporated compare | 0.51% |
| VTRS Viatris Inc. compare | −0.02% |
| HIMS Hims & Hers Health, Inc. compare | −11.4% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on RDY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement